Navigation Links
Comparative Study Confirms Enox Biopharma's Antimicrobial Superiority to Commercially Available Silver Coated Catheters
Date:8/9/2011

VANCOUVER, British Columbia, Aug. 9, 2011 /PRNewswire/ -- Enox Biopharma, Inc., a leader in nitric oxide delivery technology for the prevention of hospital acquired infections today announced on line publication of scientific results demonstrating superior efficacy in blocking growth of E.coli on the surface of nitric oxide releasing devices as compared to current market leader's silver coated catheters. The paper was published by Professor Yossef Av-Gay's lab at the University of British Columbia.

Enox's nitric oxide device technology renders medical devices like catheters and endotracheal tubes antimicrobial by sequestering nitric oxide within them in a stable state. Nitric Oxide, which is released by the device over a period of about 2 weeks once used clinically, is a potent antimicrobial agent without the drug resistance issues that plague antibiotics. Previous peer reviewed publications have demonstrated the antimicrobial properties of catheters treated with our technology in comparison to untreated catheters.

The paper titled "Comparative efficacy of commercially available and emerging antimicrobial urinary catheters against E. coli infection in vitro" was published in the August 2011 issue of the peer reviewed journal UROLOGY. The paper reports results from an investigation of the ability of four different types of catheters to prevent growth of microorganisms suspended in fluid medium (planktonic growth) and on the surface of catheters in the form of a biofilm. The study compared a non-antimicrobial catheter, an Enox nitric oxide releasing catheter, a silver coated catheter and an antibiotic coated catheter. The study concluded that both the Enox and antibiotic catheters were effective in preventing planktonic growth and biofilm formation whereas the silver and uncoated catheters were not.

"This study confirms the superiority of nitric oxide as an antimicrobial," commented Professor Av-Gay, who is the President and Founder of Enox Biopharma. "Silver proved to be as ineffective as a non-antimicrobial catheter whereas both the Enox and antibiotic catheters were very effective in reducing and eliminating microorganisms. It must be realized that Enox's ability to do this without antibiotics is a significant advantage as use of nitric oxide avoids the antibiotic resistance issues that come with the use of antibiotics."

John Rewcastle, Ph.D., Chief Executive Officer of Enox, commented, "Recently published clinical results completely independent of Enox have shown silver to not perform as well as hoped in a clinical setting. The results from the current study substantiate these observations and provide a scientific foundation for this disappointment. Enox is uniquely positioned to truly render medical devices antimicrobial without the use of antibiotics to reduce hospital acquired infections which represent a major health risk worldwide and a significant financial burden to healthcare systems."

About Enox Biopharma Inc.

Enox Biopharma, Inc. is an emerging biotechnology company with proprietary methods to sequester nitric oxide (NO) into medical devices to make them antimicrobial. The innate immune system uses NO to block microbial growth - embedding NO into medical devices makes them antimicrobial. Enox's device technology is applicable to any indwelling polymer medical device including, but not limited to catheters, endotracheal tubes and central venous catheters. Infections from these devices, which are often not reimbursed by Medicare, represent a massive financial burden to healthcare systems worldwide.

For more information, please contact:

John C. Rewcastle, Ph.D, CEO or
Itamar David, CFO
Enox Biopharma, Inc.
604.637.9744 phone

888.224.7259 fax
info@enoxbiopharma.com
www.enoxbiopharma.com


'/>"/>
SOURCE Enox Biopharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Reportlinker Adds Generic and innovative drug market in CE countries 2011 - Comparative analysis, reimbursement policies and development forecasts for 2011-2013
2. Federal Government Selects Thomson Reuters to Build Tool That Streamlines Comparative Effectiveness Research
3. Special Issue of PharmacoEconomics to Focus on Comparative Effectiveness Research
4. Stereotaxis Announces First-Ever, Prospective, Comparative Clinical Trial Outcome for VT Patients
5. QRxPharma Successfully Completes Comparative Phase 1 Proof-of-Concept Study for MoxDuo(R) CR Tablet Formulation
6. New National Pharmaceutical Council Report Provides Guidance on Evaluating Comparative Effectiveness Studies
7. Tamaulipas Comparative Wound Healing Test Treatment Successfully Concluded
8. Prospective Clinical Advantages of Trabecular Metal(TM) Technology Highlighted in Comparative Study
9. QRxPharma Successfully Completes Comparative Study for Dual-Opioid(TM) Pain Therapy
10. Comparative Study Shows Significant Bone In-growth and Advanced Clinical Outcomes Using Zimmers Trabecular Metal(TM) Technology
11. MAP Pharmaceuticals Reports Positive Results From Comparative Pharmacokinetic Trial for its Pediatric Asthma Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , Dec. 8, 2016  Pennsylvania Physician General ... Drug and Alcohol Programs Gary Tennis ... medications, known as benzodiazepines, developed with the help ... are medications that are frequently prescribed for anxiety ... are used with opioid pain medications, benzodiazepines pose ...
(Date:12/8/2016)... Dec. 8, 2016 True Health Diagnostics ... leading-edge laboratory services and management expertise to hospital ... , allowing more doctors and patients to benefit ... solutions. Logo - http://photos.prnewswire.com/prnh/20161208/447162LOGO ... systems, under pressure to contain costs, have struggled ...
(Date:12/8/2016)... NORWALK, Connecticut , 8. Dezember 2016 Mederi Therapeutics Inc ... Stretta-Therapie – eine nicht-operative Behandlungsmethode für gastroösophageale Refluxerkrankung (GERD) – in ... Reading ... Live ... by Professor Jun Liu, Director of Endoscopy at Wuhan Union Hospital ...
Breaking Medicine Technology:
(Date:12/8/2016)... ... 2016 , ... California Senate Bill (SB) 863, signed into law in 2012, ... and 2014, according to CompScope™ Medical Benchmarks for California, 17th Edition , a ... study, medical payments per claim in California decreased 4 percent in 2013 and then ...
(Date:12/8/2016)... San Francisco, California (PRWEB) , ... December 08, 2016 , ... ... health coaches, has raised an $18M Series B led by Canvas Ventures . ... use the capital to scale its mobile platform to serve more consumers who are ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... services from offices headquartered in Jefferson County, is announcing the launch of a ... Birmingham. , The number of homeless women and children in Birmingham has grown ...
(Date:12/8/2016)... ... December 08, 2016 , ... The Compretta Insurance Agency, a family ... in and around the Hancock County area, is announcing the launch of a charity ... , The Hancock County Food Pantry has worked for more than 30 years to ...
(Date:12/7/2016)... ... December 07, 2016 , ... DrugDev again demonstrated its dedication to ... of the early adopters completing EU-U.S. Privacy Shield Certification from the U.S. Department of ... both sides of the Atlantic with a mechanism to comply with EU data protection ...
Breaking Medicine News(10 mins):